Mumbai (Maharashtra) [India], August 14: Sanjivani Paranteral Limited (Sanjivani, The Company) (BSE: 531569), one of the emerging players in the pharmaceutical and healthcare manufacturing sector, continued to strengthen its operational performance during the year through improved efficiencies, focused execution, and a customer-centric approach across its business segments, and has announced its Unaudited Financial Results for Q1 FY27.K
Key Consolidated Financial Highlights
Highlights
Q1 FY27:
- Total Income of ₹239.90 Mn, YoY growth of 33.81%
- EBITDA of ₹43.21 Mn, YoY growth of 61.04%
- EBITDA Margin of 18.01%, YoY growth of 305 Bps
- Net Profit of ₹24.91 Mn, YoY growth of 43.94%
- Net Profit Margin of 10.38%, YoY growth of 73 Bps
- EPS of ₹2.03, YoY growth of 43.97%
Segment-wise Performance:
- Injectables: Revenue stood at ₹110.12 Mn, contributing 56.59% of revenue from operations, YoY growth of 22.54%
- Tablets: Revenue stood at ₹84.28 Mn, contributing 43.32% of revenue from operations
- Nutraceuticals: Revenue stood at ₹0.18 Mn, accounting for 0.09% of revenue from operations
Market-wise Performance:
- Exports (incl. incentives): Contributed 90.50% of revenue from operations (₹176.10 Mn), YoY growth of 33.49%, while domestic accounted for 9.50% (₹18.49 Mn)
- Core markets (Latin America, CIS, Middle East & Africa): Contributed 90.50% of revenue from operations, amounting to ₹176.10 Mn, YoY growth of 33.49%
Commenting on the performance, Mr. Ashwani Khemka, Chairman & Managing Director of Sanjivani Paranteral Limited said, “Q1 FY27 was marked by a positive start for Sanjivani Parenteral, supported by a recovery in exports and continued operational focus. The Pune IV Fluid facility is witnessing a gradual scale-up, with increasing commercialization and customer traction, while our core formulations business remains resilient.These operational developments were complemented by healthy financial performance during the quarter. Total Income registered a 33.81% YoY growth, while EBITDA increased 61.04% YoY, with EBITDA margin improving by 305 Bps to 18.01%, reflecting improved operating efficiencies and stronger business performance. Net Profit grew 43.94% YoY during the quarter, with PAT margin improving to 10.38%.Going forward, we remain focused on strengthening our manufacturing capabilities, expanding our product portfolio and enhancing our presence across domestic and international markets. We will continue to leverage improving operational efficiencies, growing customer traction and market opportunities to drive sustainable growth and create long-term value for our stakeholders.”
About Sanjivani Paranteral Limited
Sanjivani Parenteral Limited (BSE: 531569) is engaged in the pharmaceutical and healthcare manufacturing business, with a focus on delivering quality products and maintaining strong operational standards. The Company continues to strengthen its presence through operational excellence, customer-centric execution, and continuous focus on quality and compliance.
With a commitment towards sustainable growth and long-term value creation, the Company continues to focus on enhancing manufacturing capabilities, improving efficiencies, and expanding its business presence across key markets.
For FY26, the company has reported Total Income of ₹ 697.56 Mn, EBITDA of ₹ 114.00 Mn & PAT of ₹ 66.94 Mn on consolidated basis.
Disclaimer: This article is for informational purposes only and does not constitute financial advice.
